エボラ出血熱治療薬・ワクチン市場レポート：動向、予測、競合分析 (2031年まで)

世界のエボラ出血熱治療薬・ワクチン市場の将来は、病院・診療所市場と外来手術センター市場に機会があり、有望視されています。世界のエボラ出血熱治療薬・ワクチン市場は、2025年から2031年までのCAGRが28.6%で、2031年までに推定2億1,700万米ドルに達すると予想されます。この市場の主な促進要因は、感染症の流行が拡大していること、エボラ研究やエボラ出血熱治療薬・ワクチンの開発に対する政府の取り組みが支持されていることです。

• Lucintel社の予測では、ウイルス株の種類別ではザイールが予測期間中に最も高い成長を遂げる見込みです。
• 地域別では、人獣共通感染症の流行が拡大していること、先進医療技術の導入が進んでいること、同地域には確立された医療インフラが存在することから、北米が引き続き最大の地域となります。

エボラ出血熱治療薬・ワクチン市場の戦略的成長機会

エボラ出血熱治療薬・ワクチン市場には、特に医薬品開発、製造、流通の分野でいくつかの成長機会があります。疾病発生時により迅速で効果的な介入を求める需要が、こうした市場開拓の原動力となっています。ここでは、用途別に5つの重要な成長機会を紹介する：

• 拡大するmRNAワクチン・プラットフォーム：エボラワクチンの開発に用いられるmRNA技術は、主要な拡大分野です。COVID-19でmRNA技術の使用に成功したことで、エボラワクチンの製造と普及に応用できる可能性が広がり、アウトブレイク時の対応に画期的な変化をもたらす可能性があります。
• 高リスク地域での現地生産ワクチン：西アフリカのようにエボラ出血熱が流行しやすい地域でワクチン製造施設に投資することは、大規模な成長をもたらす可能性があります。現地生産により、世界・サプライ・チェーンへの依存を減らすと同時に、反応時間を短縮し、地域の準備態勢と回復力を向上させることができます。
• 複数病原体ワクチンの開発：エボラウイルス感染症（EVD）を含む複数の病原体を防御できる免疫原を設計するアプローチも普及しています。これにより、異なる感染症を対象とした予防接種活動の連携が改善され、より広範な予防を効率的に行うことができます。
• 世界ヘルス・イニシアティブのための協力：政府、NGO、製薬企業が協力することで、ワクチンの研究開発や提供体制を世界規模で拡大することができます。このようなパートナーシップは、ウイルス性出血熱の患者を治療するための抗体治療に関する革新的な対策に必要な資源をプールし、より利用しやすくすることができます。
• 抗体治療の進歩：EVDの治療オプションとしてのモノクローナル抗体治療薬は、まだ長い道のりがありますが、将来の開発と商業的利用のための魅力的な手段です。抗体医薬は、高リスク集団に即座に予防効果をもたらすと同時に、すでに感染している人々の生存率を高め、ワクチン接種キャンペーンを補完することができます。

技術革新を促進し、製造能力を向上させ、世界のリーチを拡大することで、これらの戦略的成長分野は、エボラ出血熱治療薬・ワクチン市場の風景を変える可能性があります。その結果、エボラ出血熱の次の流行に対して、より強力で効果的な対応が可能になると思われます。

エボラ出血熱治療薬・ワクチン市場の促進要因・課題

エボラ出血熱治療薬・ワクチン市場の発展と成長には、いくつかの市場促進要因・課題が影響します。これらには、技術的進歩、経済的側面、規制上の考慮事項が含まれます。この市場には、5つの主要促進要因と3つの主要課題があります。

エボラ出血熱治療薬・ワクチン市場を牽引する要因は以下の通り：

• ワクチン開発の技術革命：mRNAやウイルスベクター・プラットフォームなどのワクチン技術の進歩により、より効率的で即効性のあるエボラワクチンが開発されています。こうした開発は、エボラ出血熱の発生を管理する世界の能力を強化するために不可欠です。
• 政府および世界保健機関の支援の増加：各国政府と世界保健機関は、エボラ出血熱の研究とワクチン開発に多額の投資を行っています。こうした支援は、臨床試験を前進させ、規制当局から必要な承認を取得し、ワクチンを広く流通させるための基本です。
• 予防医療に対する需要の高まり：エボラ出血熱の潜在的影響に対する認識の高まりは、ワクチンなどの予防対策に対する需要を生み出しています。この需要は、特にエボラ出血熱が発生しやすい高リスク地域での市場を牽引しています。
• ワクチン製造能力の拡大：市場の重要な促進要因のひとつは、世界的、特にアフリカ全域でのワクチン製造の拡大です。現地生産により迅速な対応が可能となり、外部供給への依存度が低下するため、将来のアウトブレイクへの備えが容易になります。
• 官民パートナーシップとコラボレーション：公共部門が民間部門と協力することで、エボラ出血熱治療薬・ワクチン市場における技術革新へのアクセスが容易になります。このような協力関係は、リソース、スキル、資金をプールするのに役立ち、それによって医薬品やワクチンの開発プロセスを加速させます。

エボラ出血熱治療薬・ワクチン市場における課題は以下の通りである：

• 規制上のハードルと承認の遅れ：複雑な規制状況を乗り切ることは困難であり、その結果、エボラ出血熱に対する新薬やワクチンの承認や流通に遅れが生じる可能性があります。その結果、このような遅延が発生時の国際的な対応に支障をきたす可能性があります。
• サプライチェーンと流通の課題：十分なインフラが整っていない遠隔地への医薬品やワクチンの輸送は、依然として問題が多いです。コールドチェーンの物流や輸送に関する問題は、救命治療へのタイムリーなアクセスを妨げる可能性があります。
• ワクチン嫌いと一般市民の認識：予防接種の普及は、誤った情報や不信感によるワクチンへのためらいによって妨げられています。予防接種キャンペーンを成功させるためには、エボラワクチンの一般市民の認識と受容に取り組む必要があります。

エボラ出血熱医薬品・ワクチン市場における効果的な治療法の開発と流通に内在する複雑性は、その主な促進要因・課題によって明らかにされています。技術革新と世界の協力体制がこの状況を一変させたとはいえ、こうしたブレークスルーが現実のものとなるためには、規制や物流の障害を克服する必要があります。

目次

第1章 エグゼクティブサマリー

第2章 世界のエボラ出血熱治療薬・ワクチン市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2019年～2031年)

• マクロ経済動向 (2019～2024年) と予測 (2025～2031年)
• 世界のエボラ出血熱治療薬・ワクチン市場の動向 (2019～2024年) と予測 (2025～2031年)
• 世界のエボラ出血熱治療薬・ワクチン市場：新薬の種類別
  • Zmapp
  • Favipiravir
  • Gs-5734
  • Tkm-Ebola
  • Avi-7537
• 世界のエボラ出血熱治療薬・ワクチン市場：ワクチンの種類別
  • Cad3-Zebov
  • Rvsv-Zebov
  • その他
• 世界のエボラ出血熱治療薬・ワクチン市場：ウイルス株の種類別
  • ザイール
  • スーダン
  • タイ森林
  • レストン
  • Bundibugyoウイルス
• 世界のエボラ出血熱治療薬・ワクチン市場：最終用途別
  • 病院・クリニック
  • 外来手術センター
  • その他

第4章 地域別の市場動向と予測分析 (2019年～2031年)

• 世界のエボラ出血熱治療薬・ワクチン市場：地域別
• 北米のエボラ出血熱治療薬・ワクチン市場
• 欧州のエボラ出血熱治療薬・ワクチン市場
• アジア太平洋のエボラ出血熱治療薬・ワクチン市場
• その他地域のエボラ出血熱治療薬・ワクチン市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界のエボラ出血熱治療薬・ワクチン市場の成長機会：新薬の種類別
  • 世界のエボラ出血熱治療薬・ワクチン市場の成長機会：ワクチンの種類別
  • 世界のエボラ出血熱治療薬・ワクチン市場の成長機会：ウイルス株の種類別
  • 世界のエボラ出血熱治療薬・ワクチン市場の成長機会：最終用途別
  • 世界のエボラ出血熱治療薬・ワクチン市場の成長機会：地域別
• 世界のエボラ出血熱治療薬・ワクチン市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のエボラ出血熱治療薬・ワクチン市場の生産能力拡大
  • 世界のエボラ出血熱治療薬・ワクチン市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services
• Hemispherx Biopharma
• BioCryst Pharmaceuticals
• NanoViricides
• NewLink Genetics

The future of the global Ebola drug and vaccine market looks promising with opportunities in the hospital & clinic and ambulatory surgical center markets. The global Ebola drug and vaccine market is expected to reach an estimated $217 million by 2031 with a CAGR of 28.6% from 2025 to 2031. The major drivers for this market are the growing prevalence of infectious diseases and supportive government initiatives toward Ebola research and the development of Ebola drugs and vaccines.

• Lucintel forecasts that, within the strain type category, zaire is expected to witness the highest growth over the forecast period.
• In terms of regions, North America will remain the largest region due to the growing prevalence of zoonotic diseases, the rising adoption of advanced medical technologies, and the presence of well-established healthcare infrastructure in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market is a fast-changing environment where new technologies, partnerships, and regulatory frameworks are emerging to deal with the virus more effectively. These trends show a growing focus on global health security and innovation. Here are five key trends changing this market:

• Increased Emphasis on mRNA Vaccine Technology: The success of mRNA vaccines in COVID-19 has generated interest in using similar technology against Ebola. Companies are exploring mRNA platforms for faster and better vaccines. This could change how quickly new vaccines come to market during outbreaks.
• Scaling Up Global Vaccine Manufacturing Capacity: There is a strong move to expand vaccine manufacturing capacity globally, especially in Africa, to meet global demand. Local production minimizes dependence on imports and increases response time during outbreaks, improving preparedness and equitable distribution of the vaccine.
• Development of Therapeutic Antibodies: Monoclonal antibodies are being explored as an option for Ebola therapy, implying targeted treatment. This helps fill gaps left by vaccines by offering immediate protection and treatment options, particularly for those already infected or at high risk.
• Strengthening Global Health Partnerships: Public-private partnerships have become common, with government, non-governmental organizations, and pharmaceutical companies collaborating to drive innovation and access. These resources facilitate the mobilization of resources to hasten the development and dissemination of Ebola vaccinations and medications.
• Regulatory Harmonization and Fast-Track Approvals: Regulatory agencies are increasingly working together to harmonize standards and fast-track approvals for Ebola drugs and vaccines. Safe treatments reaching markets faster during emergencies enhance global health response efforts, making this an important trend.

These trends are thus collectively reshaping the Ebola drug and vaccine market, driving innovation, expanding access, and enhancing global preparedness. As they continue to evolve, these trends will likely result in more effective and equitable responses to managing Ebola outbreaks around the world.

Recent Developments in the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has experienced several significant developments aimed at ensuring global preparedness and response to the virus. These include new drug approvals and strategic alliances, among others. Here are five key developments that have major implications for the market:

• FDA Approval of Inmazeb: As the first-line treatment for Ebola, the FDA has approved Regeneron's Inmazeb, a combination of three monoclonal antibodies. The approval signifies an important milestone toward the provision of effective therapies for infected individuals, potentially lowering death tolls in subsequent outbreaks.
• WHO Prequalification of Johnson & Johnson's Zabdeno/Mvabea: The World Health Organization has prequalified Johnson & Johnson's two-shot Ebola vaccine regimen, known as Zabdeno/Mvabea, for emergency use. This move enhances global uptake of the vaccine, especially in areas with poor healthcare infrastructure, improving preventive measures against Ebola.
• Expansion of Manufacturing Facilities in Africa: Several pharmaceutical firms have announced intentions to establish vaccine manufacturing plants within Africa to increase local production during outbreaks, which will be much faster than relying on foreign suppliers when urgent distribution is needed.
• Strategic Collaboration Between GAVI and CEPI: The partnership between GAVI, The Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) has been strengthened to facilitate the development and equitable distribution of vaccines against Ebola disease. Therefore, this cooperation is essential for rapidly reaching at-risk populations through vaccination interventions.

By improving therapy options while expanding access and upgrading manufacturing capabilities, these developments are expected to have a significant impact on the Ebola drug and vaccine market. Combined, they create conditions for more effective global responses to future outbreaks of Ebola.

Strategic Growth Opportunities for Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has several growth opportunities, particularly in the areas of drug development, manufacturing, and distribution. The demand for faster and more effective interventions during disease outbreaks drives these openings. Here are five significant opportunities for growth by application:

• Expanding mRNA Vaccine Platforms: mRNA technologies used to develop Ebola vaccines represent a major area of expansion. The successful use of mRNA technology during COVID-19 has opened up the possibility of its application in Ebola vaccine production and dissemination, which may be game-changing for responses during outbreaks.
• Locally Produced Vaccines in High-Risk Areas: Investing in vaccine production facilities within regions like West Africa that are prone to Ebola outbreaks can result in massive growth. Local manufacturing reduces reliance on global supply chains while hastening reaction times, thereby improving regional preparedness and resilience.
• Development of Multi-Pathogen Vaccines: One increasingly popular approach involves designing immunogens capable of protecting against multiple pathogens, including Ebola virus disease (EVD). This could improve coordination between immunization efforts targeted at different infectious diseases, offering broader protection with greater efficiency.
• Collaboration for Global Health Initiatives: Collaborations between governments, NGOs, and pharmaceutical companies can scale up vaccine R&D and delivery mechanisms worldwide. Such partnerships can pool the resources needed for innovative measures regarding therapeutic antibodies for treating patients with viral hemorrhagic fever, leading to greater accessibility.
• Progress in Therapeutic Antibody Treatment: Monoclonal antibody therapeutics as treatment options for EVD have a long way to go but still represent an attractive avenue for future developments and commercial exploitation. They can provide immediate protection to high-risk population groups while increasing survival rates among those already infected, complementing vaccination campaigns.

By fostering innovation, increasing manufacturing capabilities, and expanding global reach, these strategic growth areas could change the landscape of the Ebola drug and vaccine market. Consequently, they would likely lead to a much stronger and more effective response to the next outbreak of Ebola.

Ebola Drug and Vaccine Market Driver and Challenges

Several drivers and challenges influence the development and growth of the Ebola drug and vaccine market. These encompass technological advances, economic aspects, and regulatory considerations. There are five major drivers and three key challenges that affect this market.

The factors driving the Ebola drug and vaccine market include:

• Technological Revolution for Vaccine Development: Progress in vaccine technology, such as mRNA or viral vector platforms, has led to faster-acting Ebola vaccines that are more efficient. These developments are vital for enhancing global capacities to manage outbreaks.
• Increasing Government and Global Health Organization Support: Governments and global health organizations are investing heavily in Ebola research and vaccine development. This backing is fundamental for moving clinical trials forward, acquiring necessary approvals from regulators, and ensuring widespread distribution of vaccines.
• Rising Demand for Preventive Healthcare: The rising awareness of Ebola's potential impact has generated demand for preventive measures, such as vaccines. This demand drives the market, especially in high-risk areas where outbreaks of Ebola are more likely.
• Expansion of Vaccine Manufacturing Capabilities: One important driver in the market is the growth of vaccine manufacturing worldwide, particularly across Africa. Localized production provides quicker response times and reduces dependence on external supplies, making it easier to prepare for future outbreaks.
• Public-Private Partnerships and Collaborations: The public sector working jointly with the private sector facilitates access to innovation within the Ebola drug and vaccine market. These collaborations help pool resources, skills, and finances, thereby speeding up drug and vaccine development processes.

Challenges in the Ebola drug and vaccine market include:

• Regulatory Hurdles and Approval Delays: Navigating a complex regulatory landscape can be challenging, resulting in delays in the approval or distribution of new drugs or vaccines against Ebola. Consequently, these delays can hinder international responses to an outbreak.
• Supply Chain and Distribution Challenges: Transporting medicines and vaccines to remote areas lacking sufficient infrastructure remains problematic. Issues related to cold chain logistics and transportation can hinder timely access to life-saving treatments.
• Vaccine Hesitancy and Public Perception: Widespread immunization is impeded by vaccine hesitancy driven by misinformation and mistrust. To ensure successful vaccination campaigns, public perception and acceptance of Ebola vaccines must be addressed.

The complexities inherent in the development and distribution of effective treatments for the Ebola drug and vaccine market are illuminated by its major drivers and challenges. Although technological innovation and global collaboration have transformed this situation, it is necessary to overcome regulatory and logistical impediments for these breakthroughs to become reality.

List of Ebola Drug and Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies Ebola drug and vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Ebola drug and vaccine companies profiled in this report include-

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services
• Hemispherx Biopharma
• BioCryst Pharmaceuticals
• NanoViricides
• NewLink Genetics

Ebola Drug and Vaccine by Segment

The study includes a forecast for the global Ebola drug and vaccine market by novel drug type, vaccine type, strain type, end use, and region.

Ebola Drug and Vaccine Market by Novel Drug Type [Analysis by Value from 2019 to 2031]:

• Zmapp
• Favipiravir
• Gs-5734
• Tkm-Ebola
• Avi-7537

Ebola Drug and Vaccine Market by Vaccine Type [Analysis by Value from 2019 to 2031]:

• Cad3-Zebov
• Rvsv-Zebov
• Others

Ebola Drug and Vaccine Market by Strain Type [Analysis by Value from 2019 to 2031]:

• Zaire
• Sudan
• Tai Forest
• Reston
• Bundibugyo Virus

Ebola Drug and Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Ebola Drug and Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has experienced significant advancements driven by global efforts to combat the deadly virus. With ongoing outbreaks and the potential for future epidemics, governments and pharmaceutical companies are intensifying their research and development efforts. This has led to accelerated approvals, increased funding, and the introduction of new therapies and vaccines. Key countries like the United States, China, Germany, India, and Japan are at the forefront of these developments.

• United States: The U.S. has been a leader in Ebola research, with recent developments including FDA approval for the Ervebo vaccine and deployment of monoclonal antibody treatments like Inmazeb. Moreover, the government continues to fund research for next-generation vaccines and therapeutics that will ensure preparedness for potential outbreaks while enhancing global health security.
• China: By partnering with African nations and international organizations, China has increased its focus on Ebola. Recent developments include approval of the Ad5-EBOV vaccine developed by CanSino Biologics, which is part of a broader strategy to enhance its influence in global health matters and support pandemic preparedness initiatives.
• Germany: As part of its commitment to the global healthcare industry, developmental efforts toward Ebola are ongoing. Recent developments involve collaborations with international organizations aimed at developing new vaccine candidates and treatments. Additionally, Germany is supporting African nations by funding them and providing technical assistance to strengthen their healthcare systems and response capacities.
• India: India is emerging as a major manufacturer of Ebola vaccines. Recent developments include Bharat Biotech's efforts to scale up production capabilities to manufacture these vaccines on a large scale. At the same time, the nation's pharmaceutical sector produces generic versions of Ebola treatments, making them more affordable for developing countries.
• Japan: Japan is focused on innovative ways to treat or prevent the spread of Ebola. Recent developments include the discovery of new antiviral drugs and the creation of rapid diagnostic tools. Finally, Japan's commitment to global health is demonstrated through its contributions to international research collaborations and funding for vaccine development.

Features of the Global Ebola Drug and Vaccine Market

Market Size Estimates: Ebola drug and vaccine market size estimation in terms of value ($M).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Ebola drug and vaccine market size by various segments, such as by novel drug type, vaccine type, strain type, end use, and region in terms of ($M).

Regional Analysis: Ebola drug and vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different novel drug types, vaccine types, strain types, end uses, and regions for the Ebola drug and vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Ebola drug and vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the Ebola drug and vaccine market by novel drug type (zmapp, favipiravir, gs-5734, tkm-Ebola, and avi-7537), vaccine type (cad3-zebov, rvsv-zebov, and others), strain type (zaire, sudan, tai forest, reston, and bundibugyo virus), end use (hospitals & clinics, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ebola Drug and Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Ebola Drug and Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Ebola Drug and Vaccine Market by Novel Drug Type
  • 3.3.1: Zmapp
  • 3.3.2: Favipiravir
  • 3.3.3: Gs-5734
  • 3.3.4: Tkm-Ebola
  • 3.3.5: Avi-7537
• 3.4: Global Ebola Drug and Vaccine Market by Vaccine Type
  • 3.4.1: Cad3-Zebov
  • 3.4.2: Rvsv-Zebov
  • 3.4.3: Others
• 3.5: Global Ebola Drug and Vaccine Market by Strain Type
  • 3.5.1: Zaire
  • 3.5.2: Sudan
  • 3.5.3: Tai Forest
  • 3.5.4: Reston
  • 3.5.5: Bundibugyo Virus
• 3.6: Global Ebola Drug and Vaccine Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Ambulatory Surgical Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Ebola Drug and Vaccine Market by Region
• 4.2: North American Ebola Drug and Vaccine Market
  • 4.2.1: North American Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.2.2: North American Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.3: European Ebola Drug and Vaccine Market
  • 4.3.1: European Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.3.2: European Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.4: APAC Ebola Drug and Vaccine Market
  • 4.4.1: APAC Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.4.2: APAC Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.5: ROW Ebola Drug and Vaccine Market
  • 4.5.1: ROW Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.5.2: ROW Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Novel Drug Type
  • 6.1.2: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Vaccine Type
  • 6.1.3: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Strain Type
  • 6.1.4: Growth Opportunities for the Global Ebola Drug and Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Region
• 6.2: Emerging Trends in the Global Ebola Drug and Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Ebola Drug and Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ebola Drug and Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Arbutus Biopharma
• 7.2: GlaxoSmithKline
• 7.3: Johnson & Johnson Services
• 7.4: Hemispherx Biopharma
• 7.5: BioCryst Pharmaceuticals
• 7.6: NanoViricides
• 7.7: NewLink Genetics